New Delhi, April 18 -- Eli Lilly and Company announced on Friday positive topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control despite diet and exercise alone.

According to an official statement from Eli Lilly and Company, "Orforglipron is the first oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water restrictions, to successfully complete a Phase 3 trial."

"If approved, the company is confident in its ability to launch orforglipron worldwide without supply constraints, " it said.

This would further Lilly's mission to reduce chronic diseases like type 2 diabetes, which is...